Jazz Presents New Data on Xywav & Sunosi at Virtual SLEEP 2020

Jazz Pharmaceuticals plc will present 10 abstracts at Virtual SLEEP 2020. The presentations will debut data across Jazz’s neuroscience therapeutic area, featuring new insights into the company’s ongoing sleep medicine research.

“At Jazz, we understand that sleep disorders can impact everyday life, which is why we are focused on identifying and developing innovative therapies for people with serious sleep disorders,” says Robert Iannone, MD, MSCE, executive vice president, research and development of Jazz Pharmaceuticals, in a release. “Our goal is to think more holistically about patients’ health so they can live fuller lives and our purpose is to innovate to transform the lives of patients. We are proud to present research at SLEEP on our meaningful therapeutic options for these patients with lifelong, chronic sleep disorders.”

Highlights from Jazz at Virtual SLEEP 2020 will include presentations on Xywav (calcium, magnisium, potassium and sodium oxybate) oral solution (JZP-258), a lower sodium oxybate (LXB) indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The company will also feature two poster presentations on the effects of Sunosi® (solriamfetol) on driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy.

Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution (JZP-258) Poster Presentations

Quality of Life in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults With Narcolepsy With Cataplexy

JZP-258 Dose Titration and Transition From Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Narcolepsy With Cataplexy

Cataplexy-Free Days in a Phase 3, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of JZP-258 in Adults With Narcolepsy With Cataplexy

Xyrem (sodium oxybate) oral solution Poster Presentation

Effects of Sodium Oxybate (SXB) on Body Mass Index (BMI) in Pediatric Patients With Narcolepsy

Sunosi (solriamfetol) Poster Presentations

Effects of Weight Loss During Long-Term Solriamfetol Treatment on Cardiometabolic Indices

Effects of Solriamfetol on Driving Performance in Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea

Effects of Solriamfetol on 24-Hour Blood Pressure Patterns in Participants with Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea

Epworth Sleepiness Scale Test-Retest Reliability Analysis in Solriamfetol Studies

Effects of Solriamfetol on Driving Performance in Participants With Narcolepsy

Effects of Solriamfetol on 24-Hour Blood Pressure Patterns in Participants with Excessive Daytime Sleepiness Associated With Narcolepsy

from Sleep Review https://ift.tt/2QxN2u9